Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals International, a specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics, has posted total revenues of $565.03m for the first quarter ended 31 March 2011, compared to $219.64m for the same period in 2010.
Subscribe to our email newsletter
The company has reported a net income was $6.48m, or $0.02 per diluted share, compared to a net loss of $3.15m, or $0.02 loss per diluted share, for the same period in 2010.
For the first quarter of 2011, the company’s operating income was $75.13m, compared to $16.37m for the same period in 2010.
Valeant Pharma chairman and CEO Michael Pearson said their performance in the first quarter is a strong start to what they believe will be another successful year for the company.
"Our specialty businesses performed well and our branded generic operations, in particular Central Europe, exceeded our expectations this quarter," Pearson said.